# Effect of FluoRoquinolones on Aortic Growth, aortic stIffness and wave refLEctionS (FRAGILES study)

**Authors:** Vasiliki Gardikioti, Christos Georgakopoulos, Eirini Solomou, Emilia Lazarou, Konstantinos Fasoulakis, Dimitrios Terentes-Printzios, Konstantinos Tsioufis, Dimitrios Iliopoulos, Charalambos Vlachopoulos

PMC · DOI: 10.3390/life14080992 · 2024-08-09

## TL;DR

This study found that short-term use of fluoroquinolone antibiotics does not significantly affect aortic stiffness or size in the short term.

## Contribution

FRAGILES is the first study to investigate the effects of fluoroquinolones on arterial biomarkers and aortic dimensions.

## Key findings

- No significant differences in carotid–femoral pulse wave velocity between fluoroquinolone and control groups.
- Aortic diameters and arterial biomarkers remained unchanged in both groups after 2 months of treatment.

## Abstract

Background: The widespread use of fluoroquinolones has been associated with the formation, dissection, and rupture of aortic aneurysms. Arterial biomarkers are established predictors of cardiovascular events. The present study was designed to investigate the effect of quinolones on arterial stiffness and aortic size for the first time. Methods: We studied 28 subjects receiving short-term (<15 days) antibiotic therapy involving quinolones and 27 age- and sex-matched subjects receiving an alternative to quinolone antibiotics. The follow-up period was approximately 2 months. The study’s primary endpoint was the carotid–femoral pulse wave velocity (cfPWV) difference between the two groups 2 months after therapy initiation. Secondary endpoints were the augmentation index corrected for heart rate (AIx@75) and sonographically assessed aortic diameters 2 months after the initial treatment. Results: Subjects had similar values of arterial biomarkers, blood pressure measurements, and aortic diameters at baseline. At follow-up, no significant change was observed between the two groups regarding the hemodynamic parameters and arterial biomarkers (p > 0.05 for all), i.e., cfPWV (7.9 ± 2.6 m/s for the control group vs. 8.1 ± 2.4 m/s for the fluoroquinolones group; p = 0.79), AIx@75 (22.6 ± 9.0% for the control group vs. 26.6 ± 8.1% for the fluoroquinolones group; p = 0.09), and aortic diameters. Conclusions: To our knowledge, FRAGILES is the first study to provide insights into the possible effects of fluoroquinolones on arterial biomarkers, showing that, at least in the short term, treatment with fluoroquinolones does not affect aortic function and diameter.

## Linked entities

- **Chemicals:** quinolones (PubChem CID 6038)

## Full-text entities

- **Diseases:** dissection (MESH:D000784), arterial stiffness (MESH:C566112), aortic aneurysms (MESH:D001014), rupture of (MESH:D012421)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11355559/full.md

---
Source: https://tomesphere.com/paper/PMC11355559